everydayhealth.com
Dec 18, 2024, 03:40
Akhil Santhosh: Atezolizumab and Nab-paclitaxel still remain as one of the options for mTNBC
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on LinkedIn:
“Atezolizumab and Nab-paclitaxel still remain as one of the options for mTNBC, but we should be wary of these 2 negative studies
- IMpassion 131: the same atezolizumab combination with conventional paclitaxel didn’t show benefit
- IMpassion 132: atezolizumab and chemotherapy don’t work in early progressors.”
More posts featuring Akhil Santhosh.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 04:54
Feb 22, 2025, 04:49
Feb 22, 2025, 04:33
Feb 22, 2025, 04:29
Feb 22, 2025, 04:19
Feb 22, 2025, 03:56